Original articleEffects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits
Introduction
Intermittent administration of human parathyroid hormone (hPTH) has great potential as a treatment for patients with osteoporosis. Numerous studies have demonstrated that PTH has a pronounced anabolic effect on cancellous bone as a result of stimulation of bone formation in several animal models,2, 4, 5, 9, 14, 15, 17, 19, 23, 26, 28, 29, 33, 37, 38, 39, 44, 45, 47, 51, 53 and some anabolic effects of PTH on cancellous bone have also been shown in humans.10, 11, 16, 22, 30, 34, 35, 36, 41, 43 However, the effect of PTH on cortical bone in humans remains controversial. Some early clinical studies showed that cortical bone densities were reduced after PTH treatment, while cancellous bone mass increased.11, 16, 34, 41 These findings led to the speculation that the cancellous bone anabolic effect of PTH is obtained at the expense of cortical bone.
We previously showed that PTH, at both 10 and 40 μg/kg per day for 140 days (two remodeling periods), increases cortical porosity of the tibia in female rabbits, which exhibit haversian remodeling, by stimulating intracortical remodeling.13 The increased cortical porosity was compensated by periosteal and endocortical apposition so that bone mass and mechanical strength were increased. However, there is the concern that, if porosity increases during the first remodeling period prior to compensatory apposition of bone to the cortical surfaces, there may be a transient decrease in cortical bone strength that could make the bone more susceptible to fracture.
The purpose of this study is to examine the effects of PTH on the remodeling dynamics and mechanical properties of cortical bone in rabbits during the first remodeling cycle after the initiation of treatment. We used 10 μg/kg per day of PTH in this study because, in our previous study,13 a higher dose (40 μg/kg per day) resulted in mild hypercalcemia, and the rabbits did not gain weight normally compared with controls. In humans, this hypercalcemia would have skeletal effects similar to those seen in hyperparathyroidism. The lower dose is more like the dose that would be used in clinical treatment. Use of the lower dose also increased cortical porosity in our previous study.
Section snippets
Experimental design
Fifty intact female New Zealand white rabbits were purchased from Myrtle’s Rabbitry, Inc. (Thompson Station, TN). They were acclimated for a period of 1 month and housed individually in rooms maintained at 20°C on a 12 h light/12 h dark cycle and fed lab rabbit chow containing 0.5% calcium, 0.41% phosphorus, and 2.2 IU/g vitamin D3 (Diet #5736C-Y, PMI, Richmond, IN). The amount of food served was 105 g/day per animal, and water was available at all times. The rabbits were 9 months old at the
General condition
There were no significant body weight differences among groups at the beginning of the experiment (Table 1). Rabbits treated with vehicle or PTH had normal body weight gain and there were no significant differences between PTH-treated animals and respective age-matched controls at any timepoint during the study. There were no treatment-related physical signs.
Blood chemistry
There were no significant differences between PTH-treated animals and age-matched controls in any biochemical parameter (Table 2).
Discussion
This study was undertaken to evaluate the effects of hPTH(1-34) on intracortical porosity and bone strength during the first remodeling cycle (70 days) following initiation of treatment. Because it is known that PTH increases intracortical remodeling rates, the aim was to determine if there is a transient decrease in mechanical strength of cortical bone within the first remodeling cycle after the initiation of PTH treatment. The results show that, although intracortical remodeling was
Acknowledgements
The authors thank Mary Hooser, Diana Jacob, and Thurman Alvey for performing all histological procedures. This study was funded by Eli Lilly and Co., which also provided the hPTH(1-34).
References (53)
- et al.
Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats
Bone
(1995) - et al.
The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate—Is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?
Bone
(1995) - et al.
Parathyroid hormone (1-34) increases vertebral bone mass, compressive strength, and quality in old rats
Bone
(1995) - et al.
Withdrawal of parathyroid hormone treatment causes rapid resorption of newly formed vertebral cancellous and endocortical bone in old rats
Bone
(1998) - et al.
Increased trabecular bone mass in rats treated with human synthetic parathyroid hormone
Metab Bone Dis Rel Res
(1984) - et al.
The relationship between femoral bone density and calcium balance in patients with involutional osteoporosis treated with human parathyroid hormone fragment (hPTH1-34)
Metab Bone Dis Rel Res
(1981) - et al.
Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients
Bone Miner
(1991) - et al.
Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis)
Bone
(1999) - et al.
Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis
Lancet
(1997) - et al.
The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength—Assessed in a sexually mature, ovariectomized rat model
Bone
(1995)